Swiss National Bank’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$332M Buy
744,600
+42,000
+6% +$19.6M 0.19% 86
2025
Q4
$319M Sell
702,600
-37,700
-5% -$16.2M 0.19% 87
2025
Q3
$290M Sell
740,300
-38,000
-5% -$15.9M 0.17% 96
2025
Q2
$346M Buy
778,300
+52,100
+7% +$24M 0.21% 83
2025
Q1
$352M Sell
726,200
-3,000
-0.4% -$1.4M 0.25% 70
2024
Q4
$294M Sell
729,200
-36,800
-5% -$17.1M 0.2% 82
2024
Q3
$356M Buy
766,000
+1,200
+0.2% +$576K 0.23% 69
2024
Q2
$358M Sell
764,800
-6,900
-0.9% -$2.99M 0.25% 70
2024
Q1
$323M Sell
771,700
-35,400
-4% -$15M 0.23% 77
2023
Q4
$328M Sell
807,100
-21,300
-3% -$7.87M 0.24% 74
2023
Q3
$288M Sell
828,400
-101,900
-11% -$35.6M 0.23% 78
2023
Q2
$327M Sell
930,300
-88,500
-9% -$29.8M 0.22% 79
2023
Q1
$321M Sell
1,018,800
-23,600
-2% -$7.08M 0.22% 83
2022
Q4
$301M Sell
1,042,400
-65,975
-6% -$20.1M 0.22% 92
2022
Q3
$321M Buy
1,108,375
+4,100
+0.4% +$1.18M 0.23% 77
2022
Q2
$311M Buy
1,104,275
+3,100
+0.3% +$830K 0.21% 86
2022
Q1
$287M Buy
1,101,175
+115,100
+12% +$27.3M 0.16% 110
2021
Q4
$217M Sell
986,075
-37,600
-4% -$7.31M 0.13% 132
2021
Q3
$186M Sell
1,023,675
-36,300
-3% -$7.09M 0.12% 153
2021
Q2
$214M Sell
1,059,975
-429,000
-29% -$89.7M 0.13% 139
2021
Q1
$320M Buy
1,488,975
+21,500
+1% +$4.72M 0.21% 94
2020
Q4
$347M Buy
1,467,475
+77,300
+6% +$17.7M 0.25% 74
2020
Q3
$378M Buy
1,390,175
+204,400
+17% +$56.4M 0.3% 62
2020
Q2
$344M Buy
1,185,775
+149,700
+14% +$40.6M 0.29% 66
2020
Q1
$247M Buy
1,036,075
+205,900
+25% +$47.2M 0.26% 82
2019
Q4
$182M Sell
830,175
-34,800
-4% -$7.04M 0.19% 101
2019
Q3
$147M Buy
864,975
+10,866
+1% +$1.92M 0.16% 143
2019
Q2
$157M Buy
854,109
+1,200
+0.1% +$210K 0.17% 123
2019
Q1
$157M Buy
852,909
+22,000
+3% +$4.06M 0.17% 117
2018
Q4
$138M Buy
830,909
+17,400
+2% +$3.01M 0.18% 118
2018
Q3
$157M Sell
813,509
-25,300
-3% -$4.51M 0.17% 116
2018
Q2
$143M Buy
838,809
+27,400
+3% +$4.25M 0.16% 133
2018
Q1
$132M Sell
811,409
-117,600
-13% -$19.2M 0.16% 137
2017
Q4
$139M Buy
929,009
+10,800
+1% +$1.6M 0.15% 152
2017
Q3
$140M Buy
918,209
+11,100
+1% +$1.67M 0.16% 143
2017
Q2
$117M Buy
907,109
+28,300
+3% +$3.41M 0.14% 159
2017
Q1
$96.1M Buy
878,809
+189,000
+27% +$16.6M 0.12% 191
2016
Q4
$50.8M Buy
689,809
+4,800
+0.7% +$391K 0.08% 270
2016
Q3
$59.7M Sell
685,009
-5,600
-0.8% -$529K 0.1% 235
2016
Q2
$59.4M Buy
690,609
+52,200
+8% +$4.51M 0.1% 236
2016
Q1
$48.6M Buy
638,409
+193,900
+44% +$17.5M 0.09% 252
2015
Q4
$55.9M Buy
444,509
+9,500
+2% +$1.15M 0.14% 169
2015
Q3
$45.3M Buy
435,009
+44,700
+11% +$5.74M 0.12% 203
2015
Q2
$48.2M Buy
390,309
+23,900
+7% +$3.01M 0.12% 196
2015
Q1
$43.2M Buy
366,409
+145,100
+66% +$17.4M 0.12% 215
2014
Q4
$26.3M Sell
221,309
-5,000
-2% -$563K 0.1% 224
2014
Q3
$25.4M Sell
226,309
-3,500
-2% -$333K 0.1% 228
2014
Q2
$21.8M Buy
229,809
+3,300
+1% +$231K 0.08% 261
2014
Q1
$16M Sell
226,509
-21,600
-9% -$1.71M 0.06% 302
2013
Q4
$18.4M Sell
248,109
-11,700
-5% -$815K 0.07% 277
2013
Q3
$19.7M Buy
259,809
+27,600
+12% +$2.2M 0.08% 258
2013
Q2
$18.5M Buy
+232,209
New +$17.1M 0.08% 262

Other funds holding VRTX

Swiss National Bank's VRTX Position: Q1 2026 in Review

Swiss National Bank increased its Vertex Pharmaceuticals (VRTX) stake by 6% in Q1 2026, buying an estimated $19.6M and bringing the position to 744,600 shares worth $332M. The position accounts for 0.19% of the portfolio, ranked #86.

Swiss National Bank first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. The position peaked at $378M in Q3 2020. 1,691 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Swiss National Bank held 744,600 shares of Vertex Pharmaceuticals worth $332M as of Q1 2026.
  • Swiss National Bank bought 42,000 Vertex Pharmaceuticals shares in Q1 2026, an estimated $19.6M.
  • Vertex Pharmaceuticals made up 0.19% of Swiss National Bank's portfolio in Q1 2026, its #86 holding.
  • Swiss National Bank first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • Swiss National Bank's Vertex Pharmaceuticals position peaked at $378M in Q3 2020.
  • 1,691 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Swiss National Bank's 13F filing for Q1 2026, filed 7 May 2026.